Galmed announces an expansion of its activities to cancer and major cardiometabolic diseases

Aramchol is the most clinically advanced, first-in-class, stearoyl-coa desaturase1 (scd1) oral inhibitor, demonstrating in ph2 and ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line tel aviv, israel , sept.
GLMD Ratings Summary
GLMD Quant Ranking